Trial PAR008 is on ANZCTR, page-48

...yup, covered it, here is re-post (see below).

Agree though, this is prob. the closest to watch out for.



POSTED ORIGINALLY on 23rd Aug 2021:

Link to original:

https://hotcopper.com.au/threads/ipps-and-the-not-so-looney-comparison.6233941/page-10?post_id=55501980

---------------------------------------------

Nah, I'm not too worried about Lorecivivint, there has been a good peer reviewed article ² stating that no Lorecivivint groups attained a significant reduction in pain/function compared to Placebo at week 13 thus Primary endpoint was not met.

I concede that they still got at least some beneficial results with a good safety profile and the peer reviewed article also states that there could be a potential subset that would benefit from such a drug.

I glanced at their 2B results and noticed they achieved a 20 point Womac (total score) drop and I wondered how that compared to us?

A quick re-look at our results published on 3rd Feb just this year demonstrated that iPPS resulted in a massive 55.2 point Womac drop (see graphic below), thats a full 176% better point reduction than a drug like Lorecivivint.









Best to DYOR



REFERENCES

1) https://app.sharelinktechnologies.com/announcement/asx/4e6e9a6094fe8df04ee25ba70966bda3
2) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589351/